Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3549-3560

  Patel, Vyomesh ^a   Lahusen, Tyler ^a   Leethanakul, Chidchanok ^a   Igishi, Tadashi ^d   Kremer, Marcus ^c   Quintanilla Martinez, Leticia ^c   Ensley, John F ^d   Sausville, Edward A ^b   Gutkind, J Silvio ^a   Senderowicz, Adrian M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CYCLIN D3; CYCLIN DEPENDENT KINASE; PROTEIN P27; RETINOBLASTOMA PROTEIN; 7-HYDROXYSTAUROSPORINE; ALKALOID; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CDK2 PROTEIN, MOUSE; CDK4 PROTEIN, HUMAN; CDK4 PROTEIN, MOUSE; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DRUG DERIVATIVE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL CYCLE; CELL STRAIN 3T3; DOSE RESPONSE; FLOW CYTOMETRY; HEAD AND NECK TUMOR; IC 50; IMMUNOHISTOCHEMISTRY; KINETICS; METABOLISM; NUDE MOUSE; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TIME;

3T3 CELLS; ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; KINETICS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; S PHASE; STAUROSPORINE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0036847699     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Sidransky, D. Molecular genetics of head and neck cancer. Curr. Opin. Oncol., 7: 229-233, 1995
2. Leethanakul, C., Patel, V., Gillespie, J., Pallente, M., Ensley, J. F., Koontongkaew, S., Liotta, L. A., Emmert-Buck, M., and Gutkind, J. S. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene, 19: 3220-3224, 2000
3. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. (Bethesda), 81: 1088-1092, 1989
4. Monks, A., Scudiero, D., Johnson, G., Paul, K., and Sausvulle, E. A. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets. Anticancer Drug Des., 12: 533-541, 1997
5. Koutsoukos, A. D., Rubinstein, L. V., Faraggi, D., Simon, R. M., Kalyandrug, S., Weinstein, J. N., Kohn, K. W., and Paull, K. D. Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: Predicting biochemical mechanism of action. Stat. Med., 13: 719-730, 1994
6. Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., Jing, X., Roberge, M., Fuse, E., Kuwabara, T., and Senderowicz, A. M. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol., 19: 2319-2333, 2001
7. Dees, E., O'Reilly, S., Figg, W., Elza-Brown, K., Aylesworth, C., Carducci, M., Byrd, J., Grever, M., and Donehower, R. A phase I and pharmacologic study of UCN-01, a protein kinase c inhibitor. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 797, 2000
8. Tamura, T., Sasaki, Y., Minami, H., Fujii, H., Ito, K., Igarashi, T., Kamiya, Y., Kurata, T., Ohtsu, T., Onozawa, Y., Yamamoto, N., Yamamoto, N., Watanabe, Y., Tanigaara, Y., Fuse, E., Kuwabara, T., Kobayahsi, S., and Shimada, Y. Phase I study of UCN-01 by 3-hour infusion. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 159, 18, 535, 1999
9. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot. (Tokyo), 40: 1782-1784, 1987
10. Seynaeve, C. M., Kazanietz, M. G., Blumberg, P. M., Sausville, E. A., and Worland, P. J. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol. Pharmacol., 45: 1207-1214, 1994
11. Abe, S., Kubota, T., Otani, Y., Furukawa, T., Watanabe, M., Kumai, K., Akiyama, T., Akinaga, S., and Kitajima, M. UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G, phase checkpoint machinery. Jpn. J. Cancer Res., 92: 537-545, 2001
12. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51: 4888-4892, 1991
13. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000
14. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ., 6: 927-936, 1995
15. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57: 1495-1501, 1997
16. 1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine). Cancer Res., 59: 4406-4412, 1999
17. Sarkaria, J. N., Busby, E. C., Tibbetts, R. S., Roos, P., Taya, Y., Karnitz, L. M., and Abraham, R. T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res., 59: 4375-4382, 1999
18. Busby, E. C., Leistritz, D. F., Abraham, R. T., Karnitz, L. M., and Sarkaria, J. N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res., 60: 2108-2112, 2000
19. Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., and Piwnica-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem., 275: 5600-5605, 2000
20. 1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene, 18: 5691-5702, 1999
21. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics. CA - Cancer J. Clin., 51: 15-36, 2001
22. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996
23. Okami, K., Reed, A. L., Cairns, P., Koch, W. M., Westra, W. H., Wehage, S., Jen, J., and Sidransky, D. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene, 18: 3541-3545, 1999
24. Michalides, R., van Veelen, N., Hart, A., Loftus, B., Wientjens, E., and Balm, A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res., 55: 975-978, 1995
25. Sarbia, M., Stahl, M., Fink, U., Heep, H., Dutkowski, P., Willers, R., Seeber, S., and Gabbert, H. E. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int. J. Cancer, 84: 86-91, 1999
26. Mineta, H., Miura, K., Suzuki, I., Takebayashi, S., Misawa, K., Ueda, Y., and Ichimura, K. p27 expression correlates with prognosis in patients with hypopharyngeal cancer. Anticancer Res., 19: 4407-4412, 1999
27. Chen, Q., Luo, G., Li, B., and Samaranayake, L. P. Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: A semi-quantitative immunohistochemical study. J. Oral Pathol. Med., 28: 158-164, 1999
28. Kushner, J., Bradley, G., Young, B., and Jordan, R. C. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J. Oral Pathol. Med., 28: 77-81, 1999
29. Khuri, F. R., Shin, D. M., Glisson, B. S., Lippman, S. M., and Hong, W. K. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Current status and future directions. Semin. Oncol., 27: 25-33, 2000
30. Cardinali, M., Pietraszkiewicz, H., Ensley, J. F., and Robbins, K. C. Tyrosine phosphorylation as a marker for aberrantly regulated growthpromoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer. 61: 98-103, 1995
31. Yeudall, W. A., Crawford, R. Y., Ensley, J. F., and Robbins, K. C. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis (Lond.), 15: 2683-2686, 1994
32. Cardinali, M., Kratochvil, F. J., Ensley, J. F., Robbins, K. C., and Yeudall, W. A. Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. Mol. Carcinog., 18: 78-88, 1997
33. 1-S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck. Int. J. Cancer, 73: 551-555, 1997
34. Patel, V., Ensley, J. F., Gutkind, J. S., and Yeudall, W. A. Induction of apoptosis in head-and-neck squamous carcinoma cells by gamma-irradiation and bleomycin is p53-independent. Int. J. Cancer, 88: 737-743, 2000
35. Patel, V., Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. Flavopiridol, a novel cycli-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig., 102: 1674-1681, 1998
36. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59: 4634-4641, 1999
37. Senderowicz, A., and Lahusen, J. Assays for cyclin-dependent kinase inhibitors. In: J. K. Buolamwini and A. A. Adjei (eds.), Methods in Molecular Medicine, Novel Anticancer Drug Protocols. Totowa, NJ: Humana Press, 2001
38. Fiebig, H. H., Berger, D. P., Winterhalter, B. R., and Plowman, J. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat. Rev., 17: 109-117, 1990
39. Dykes, D. J., Abott, B. J., Mayo, J. G., Harrison, S. J., Laster, W. R., Simpson-Herren, L., and Grishwold, D. P. J. Development of human tumor xenograft models for in vitro evaluation of new antitumor drugs. Contrib. Oncol., 42: 1-22, 1992
40. Fowler, L., Dong, L., Bowes, R. C., III, van de Water, B., Stevens, J. L., and Jaken, S. Transformation-sensitive changes in expression, localization, and phosphorylation of adducins in renal proximal tubule epithelial cells. Cell Growth Differ., 9: 177-184, 1998
41. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25 [see comments]. Science (Wash. DC), 277: 1497-1501, 1997
42. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993
43. 1-phase accumulation. Jpn. J. Cancer Res., 90: 1364-1372, 1999
44. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy, Oncogene, 19: 6600-6606, 2000
45. Senderowicz, A. M. Cyclin-dependent kinase modulators: A novel class of cell cycle regulators for cancer therapy. In: G. G. Giaccone, R. L. R. L. Schilsky, and P. M. Sondel (eds.), Cancer Chemotherapy and Biological Response Modifiers, Vol. 19, pp. 165-188. Oxford, UK: Elsevier Science, in press, 2001
46. Mack, P. C., Gandara, D. R., Bowen, C., Edelman, M. J., Paglieroni, T., Schnier, J. B., Gelmann, E. P., and Gumerlock, P. H. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin. Cancer Res., 5: 2596-2604, 1999
47. Usuda, J., Saijo, N., Fukuoka, K., Fukumoto, H., Kuh, H. J., Nakamura, T., Koh, Y., Suzuki, T., Koizumi, F., Tamura, T., Kato, H., and Nishio, K. Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. Int. J. Cancer, 85: 275-280, 2000
48. Sherr, C. J. D-type cyclins. Trends Biochem. Sci., 20: 187-190, 1995
49. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996
50. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000
51. Yeudall, W. A., Jakus, J., Ensley, J. F., and Robbins, K. C. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol. Carcinog., 18: 89-96, 1997
52. Boukamp, P., Popp, S., Bleuel, K., Tomakidi, E., Burkle, A., and Fusenig, N. E. Tumorigenic conversion of immortal human skin keratinocytes (HaCaT) by elevated temperature. Oncogene, 18: 5638-5645, 1999
53. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. (Bethesda), 88: 956-965, 1996
54. Wilson, W. H., Sorbara, L., Figg, W. D., Mont, E. K., Sausville, E., Warren, K. E., Balis, F. M., Bauer, K., Raffeld, M., Senderowicz, A. M., and Monks, A. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm. Clin. Cancer Res., 6: 415-421, 2000
55. Lush, R., Senderowicz, A. M., Figg, W. E., Headlee, D., and Sausville, E. A. Surprising pharmacokinetics of UCN-01 in humans with cancer may be due to high plasma protein binding. Proc. Am. Assoc. Cancer Res., 38: 600, 1997
56. Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D., Figg, W., Arbuck, S. G., Senderowicz, A. M., Sausville, E. A., Akinaga, S., Kuwabara, T., and Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein. Cancer Res., 58: 3248-3253, 1998
57. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999